Dr Abby Bland

2023

Journal - Research Article

Berry, M., Bland, A., & Ashton, J. (2023). Differing cell cycle responses for alectinib and SHP099 in variant 1 and variant 3 ALK⁺ non-small cell lung cancer cell lines. Journal of Thoracic Oncology, 18(Suppl. 11), S424-S425. doi: 10.1016/j.jtho.2023.09.766

Berry, M. A., Bland, A. R., & Ashton, J. C. (2023). Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors. Scientific Reports, 13, 10041. doi: 10.1038/s41598-023-37006-2

Journal - Research Other

Ashton, J. C., Bland, A. R., & Sammut, I. A. (2023). Treatment of lorlatinib induced hypercholesterolemia with PCSK9 inhibitors: A new solution to an emerging need in non-small cell lung cancer therapy. Open Journal of Clinical & Medical Case Reports, 9(11). [Case Study].

Bland, A. R., Ashton, J. C., Kamal, M. A., & Sahebkar, A. (2023). The current evidence for the therapeutic role of curcumin in Alzheimer's disease. CNS & Neurological Disorders: Drug Targets, 22(3), 318-320. doi: 10.2174/1871527321666220119105836

Conference Contribution - Poster Presentation (not in published proceedings)

Bland, A. R., Kleffmann, T., & Ashton, J. C. (2023, August). Using next generation mass spectrometry technologies to examine protein targets of the ALK+ lung cancer drug, Alectinib. Poster session presented at the 17th New Zealand Medical Sciences Congress (MedSci), Queenstown, New Zealand.

2022

Journal - Research Article

Watts, B., Berry, M., Bland, A., Badart, M., Hawkins, B., & Ashton, J. (2022). Tumour cell suppression by spiroleucettadine through dual regulation of cell cycle and apoptosis. F1000Research, 11, 1328. doi: 10.12688/f1000research.126754.1

Johnston, H. M., Kueh, J. T. B., Hartley, R. H., Bland, A. R., Payne, F. M., Harrison, J. C., Sammut, I. A., & Larsen, D. S. (2022). Utilising fluorescent reporters to probe the mode of action of norbornen-7-one CO releasing molecules. Organic & Biomolecular Chemistry, 20, 5812-5819. doi: 10.1039/d2ob01076c

Bland, A. R., Shrestha, N., Berry, M., Wilson, C., & Ashton, J. C. (2022). Experimental determination of cancer drug targets with independent mechanisms of resistance. Current Cancer Drug Targets, 22(2), 97-107. doi: 10.2174/1568009622666220107152014

Bland, A. R., Payne, F. M., Ashton, J. C., Jamialahmadi, T., & Sahebkar, A. (2022). The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. Pharmacological Research, 175, 105986. doi: 10.1016/j.phrs.2021.105986

Journal - Research Other

Bland, A. R., Ashton, J. C., Kamal, M. A., & Sahebkar, A. (2022). The current state of evidence for the therapeutic role of curcumin in Alzheimer's disease. CNS & Neurological Disorders: Drug Targets, 21. doi: 10.2174/1871527321666220119105836

Conference Contribution - Published proceedings: Abstract

Dabb, A. R., Thwaite, S. H., Payne, F. M., Bland, A. R., Harrison, J. C., & Sammut, I. A. (2022). The cardioprotective agent oCOm-21 inhibits NLRP3 inflammasome assembly in cardiac ischaemia reperfusion injury. In L. Wilson, H. Harcombe, P. Jayakaran, L. Burga, J. Antony, K. Morgaine, M. Garelja, A. Middleton, M. Anwar & T. Milne (Eds.), Proceedings of the 264th Otago Medical School Research Society (OMSRS) Meeting: Masters/Honours Student Speaker Awards. Dunedin, New Zealand: OMSRS. Retrieved from https://ourarchive.otago.ac.nz/handle/10523/12839

Conference Contribution - Poster Presentation (not in published proceedings)

Bland, A. (2022, August). Using 'turn on' fluorescent probes to study the cellular target and delivery of carbon monoxide using novel organic releasing molecules. Poster session presented at the Metabolic & Cardiovascular Disease Satellite Meeting: Queenstown Research Week, Queenstown, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

Bland, A. R., Sammut, I. A., Rosengren, R. J., & Ashton, J. A. (2022, August). An old drug with new tricks: Examining the anti-cancer potential of metformin in EML₄-ALK+ non-small cell lung cancer. Verbal presentation at the Cancer Satellite Meeting: Queenstown Research Week, Queenstown, New Zealand.

Watts, B. A., Berry, M., Bland, A. R., Hawkins, B. C., & Ashton, J. C. (2022, August-September). Tumour cell suppression by Spiroleucettadine through dual regulation of cell cycle and apoptosis. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) NZ Annual Scientific Meeting, Queenstown, New Zealand.

Berry, M. A., Bland, A. R., & Ashton, J. C. (2022, August-September). Combination of ALK and SHP2 inhibitors produce synergistic suppression of ALK-positive lung cancer cell growth. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) NZ Annual Scientific Meeting, Queenstown, New Zealand.

Payne, F. M., Ng, Y. H., Bland, A. R., Thwaite, S. H., Diffee, G. M., Harrison, J. C., Baldi, J. C., & Sammut, I. A. (2022, August-September). Carbon monoxide release by oCOm-21 enhances Ca²⁺ sensitivity of the cardiac myofilament. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) NZ Annual Scientific Meeting, Queenstown, New Zealand.

Bland, A. R., Sammut, I. A., Rosengren, R. J., & Ashton, J. C. (2022, August-September). An old drug with new tricks: Examining the action of metformin in ALK+ lung cancer. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) NZ Annual Scientific Meeting, Queenstown, New Zealand.

2021

Journal - Research Article

Bland, A. R., & Ashton, J. C. (2021). Considerations for whole-slide analysis of murine xenografts experiments. Journal of Histochemistry & Cytochemistry, 69(10), 627-631. doi: 10.1369/00221554211046994

Badart, M. P., Barnes, E. M., Cording, A. P., Gilmer, S. C. L., Billinghurst, I. D., Edupuganti, V. V. S. R., … Bland, A. R., Bower, R. L., Rana, Z., Ferguson, S. A., Opel Reading, H. K., Cook, G. M., Rosengren, R. J., Krause, K. L., Gamble, A. B., Ashton, J. C., & Hawkins, B. C. (2021). Synthesis and biological evaluation of (-) and (+)-spiroleucettadine and analogues. ChemMedChem, 16, 1308-1315. doi: 10.1002/cmdc.202000954

Bland, A. R., Shrestha, N., Bower, R. L., Rosengren, R. J., & Ashton, J. C. (2021). The effect of metformin in EML₄-ALK+ lung cancer alone and in combination with crizotinib in cell and rodent models. Biochemical Pharmacology, 183, 114345. doi: 10.1016/j.bcp.2020.114345

Journal - Research Other

Keshavarz Shahbaz, S., Koushki, K., Ayati, S. H., Bland, A. R., Bezsonov, E. E., & Sahebkar, A. (2021). Inflammasomes and colorectal cancer. Cells, 10, 2172. doi: 10.3390/cells10092172

Radbakhsh, S., Barreto, G. E., Bland, A. R., & Sahebkar, A. (2021). Curcumin: A small molecule with big functionality against amyloid aggregation in neurodegenerative diseases and type 2 diabetes. BioFactors, 47, 570-586. doi: 10.1002/biof.1735

Conference Contribution - Published proceedings: Abstract

Bland, A. R., Shrestha, N., Bower, R. L., Rosengren, R. J., & Ashton, J. C. (2021). Repurposing the hypoglycemic agent, metformin, for targeted lung cancer. New Zealand Medical Journal, 134(1537), (pp. 110). Retrieved from https://www.nzma.org.nz/journal

Awarded Doctoral Degree

Bland, A. R. (2021). An old drug with new tricks: Examining the anti-cancer potential of metformin in mouse and cell models of EML4- ALK+ non-small cell lung cancer (PhD). University of Otago, Dunedin, New Zealand. Retrieved from http://hdl.handle.net/10523/12053

2020

Journal - Research Article

Shrestha, N., Bland, A. R., Bower, R. L., Rosengren, R. J., & Ashton, J. C. (2020). Inhibition of mitogen-activated protein kinase kinase alone and in combination with anaplastic lymphoma kinase (ALK) inhibition suppresses tumor growth in a mouse model of ALK-positive lung cancer. Journal of Pharmacology & Experimental Therapeutics, 374, 134-140. doi: 10.1124/jpet.120.266049

Journal - Research Other

Hassanzadeh, S., Read, M. I., Bland, A. R., Majeed, M., Jamialahmadi, T., & Sahebkar, A. (2020). Curcumin: An inflammasome silencer. Pharmacological Research, 159, 104921. doi: 10.1016/j.phrs.2020.104921

Bland, A. R., Shrestha, N., Rosengren, R. J., & Ashton, J. C. (2020). Does crizotinib auto-inhibit CYP3A in vivo? [Brief report]. Pharmacology, 105, 715-718. doi: 10.1159/000506996

Conference Contribution - Published proceedings: Abstract

Bland, A. R., Shrestha, N., Bower, R. L., Sammut, I. A., Rosengren, R. J., & Ashton, J. A. (2020). An old drug for new tricks: Metformin as a chemotherapeutic agent for lung cancer. New Zealand Medical Journal, 133(1527), (pp. 127-128). Retrieved from https://www.nzma.org.nz/journal

2019

Journal - Research Article

Bland, A. R., Bower, R. L., Nimick, M., Hawkins, B. C., Rosengren, R. J., & Ashton, J. C. (2019). Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer. European Journal of Pharmacology, 865, 172749. doi: 10.1016/j.ejphar.2019.172749

Shrestha, N., Lateef, Z., Martey, O., Bland, A. R., Nimick, M., Rosengren, R., & Ashton, J. C. (2019). Does the mouse tail vein injection method provide a good model of lung cancer? F1000Research, 8, 190. doi: 10.12688/f1000research.17964.1

Conference Contribution - Published proceedings: Abstract

Ashton, J., Shrestha, N., & Bland, A. (2019). Combination ALK and MEK inhibition in ALK-positive lung cancer. Journal of Thoracic Oncology, 14(10, Suppl.), (pp. S857). doi: 10.1016/j.jtho.2019.08.1851

Conference Contribution - Poster Presentation (not in published proceedings)

Shrestha, N., Bland, A. R., Bower, R. L., Nimick, M., Rosengren, R. J., & Ashton, J. C. (2019, September). Toxicity and efficacy of crizotinib and selumetinib combination therapy in in vivo xenograft model of ALK-positive lung cancer. Poster session presented at the Medical Sciences Congress (MedSci), Queenstown, New Zealand.

Bland, A. R., Shrestha, N., Bower, R. L., Sammut, I. A., Rosengren, R. J., & Ashton, J. A. (2019, September). An old drug for new tricks: Metformin as a chemotherapeutic agent for lung cancer. Poster session presented at the Medical Sciences Congress (MedSci), Queenstown, New Zealand.

2018

Conference Contribution - Published proceedings: Abstract

Bland, A., Nimick, M., & Ashton, J. (2018). Metformin in combination with crizotinib for the treatment of EML4-ALK+ lung cancer. Journal of Thoracic Oncology, 13(Suppl. 10), (pp. S460-S461). doi: 10.1016/j.jtho.2018.08.561

Bland, A. R., Rosengren, R. J., & Ashton, J. C. (2018). Curcumin derivatives as a novel strategy for overcoming crizotinib resistance in EML4-ALK+ lung cancer cell lines. New Zealand Medical Journal, 131(1470), (pp. 113). Retrieved from https://www.nzma.org.nz/journal

Conference Contribution - Poster Presentation (not in published proceedings)

Bower, R. L., Nimick, M., Shrestha, N., Bland, A., Rosengren, R., & Ashton, J. C. (2018, August). Toward a cell-based model of metastatic prostate cancer: Isolation and characterisation of metastatic prostate cancer cells derived from an orthotopically implanted SCID mouse model. Poster session presented at the Medical Sciences Congress (MedSci), Queenstown, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

Bland, A. R., & Ashton, J. C. (2018, August). Metformin in combination with crizotinib as an anti-cancer treatment for EML4-ALK+ non-small cell lung cancer. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

Bland, A. R., Bower, R. L., Rosengren, R. J., & Ashton, J. C. (2018, August). Cytotoxicity of curcumin derivatives in ALK⁺ non-small cell lung cancer cells. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

2017

Conference Contribution - Published proceedings: Abstract

Bland, A. R., Rosengren, R. J., & Ashton, J. C. (2017). Cytotoxicity of second-generation curcumin analogues in human lung adenocarcinoma cell lines. New Zealand Medical Journal, 130(1461), (pp. 89). Retrieved from http://www.nzma.org.nz/journal